Compare Cytokinetics Inc (CYTK) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MPLX LP — how do they compare? Cytokinetics Inc trades at $62.85 (market cap $8.62B), while MPLX LP trades at $56.44 (market cap $58.11B). The key difference: MPLX LP is far larger — about 6.7× Cytokinetics Inc's market cap, and MPLX LP pays a 7.51% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MPLX | |
|---|---|---|
Market Cap | $8.62B | $58.11B |
Volume | 2,594,626 | 687,483 |
Sector | Health | Energy |
52-Week High | $87.26 | $60.51 |
52-Week Low | $54.76 | $47.80 |
Typical Hold Time | 19 Days | — |
Enterprise Value | $8.72B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MPLX trades at $56.86, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and dividend payments. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure.
MPLX offers value with a 12.33 P/E ratio and strong profitability metrics, but faces headwinds from recent earnings misses and energy market volatility. The stock presents income appeal with dividend coverage, though investors should monitor execution on future earnings and energy price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
